Non-hodgkin's%20lymphoma News

News

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

20220531000000

New drug applications approved by US FDA as of 16-31 May 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Novel cellular therapy produces impressive responses in heavily pretreated CD30-positive lymphoma

Kanas Chan, 20220519031535

A novel cellular therapy that links the bispecific antibody AFM13 with cord blood–derived natural killer cells (AFM13-NK), when used at recommended phase II dose (RP2D), produces a 100 percent overall response rate (ORR) in patients with refractory or relapsed CD30-positive Hodgkin or non-Hodgkin lymphomas (HL/NHL), according to results of the NCT04074746 trial presented at American Association for Cancer Research (AACR) 2022.

Immune-related adverse events signal better survival in non-Hodgkin lymphoma patients on ICI

20220211080000

The development of immune-related adverse events (irAEs) in non-Hodgkin lymphoma (NHL) patients treated with immune checkpoint inhibitors (ICI) may indicate better long-term survival, a recent study has found.

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

Roshini Claire Anthony, 20220125180001

The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.

Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL

Roshini Claire Anthony, 20220114180001

The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.

Axi-cel CAR T-cell therapy trumps standard care in earlier-line R/R LBCL

CAR T-cell therapy trumps standard care in earlier-line lymphoma

Pearl Toh, 20211225130100

Treatment with the CAR* T-cell therapy axicabtagene ciloleucel (axi-cel) in the curative setting significantly extends event-free survival (EFS) compared with standard of care (SOC) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), according to the ZUMA-7 study presented at ASH 2021.

Lenalidomide plus R-CHOP effective for untreated DLBCL patients

20211016140000

Combining lenalidomide with R-CHOP* (R2CHOP) yields durable and high rates of treatment response in untreated patient with diffuse large B-cell lymphoma (DLBCL), a recent study has found.

Tisagenlecleucel shows durable activity in R/R aggressive large B-cell lymphomas

Christina Lau, 20210919000000

The CD19-directed chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel has demonstrated durable activity and a manageable safety profile in adult patients with relapsed or refractory (R/R) aggressive large B-cell lymphomas (LBCLs) after long-term follow-up of the JULIET trial.

Lymphoma patients at high risk of persistent COVID-19

Lymphoma patients at high risk of long COVID-19

Pearl Toh, 20210703150000

Patients with B-cell non-Hodgkin lymphoma hospitalized for COVID-19 are at an increased risk of developing persistent COVID-19 and death, according to a retrospective study presented at EHA 2021.

Copanlisib-rituximab combo extends PFS in relapsed indolent non-Hodgkin lymphoma

Roshini Claire Anthony, 20210602180001

The combination of copanlisib and rituximab extended progression-free survival (PFS) compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma, results of the phase III CHRONOS-3 trial showed.

New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations

31 Mar 2021

At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT^®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.

Immunotherapy sparks hope for paediatric ALL

Audrey Abella, 14 Oct 2020

Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).